UV-B irradiation of mononuclear cells induces an apparent abolition of the ability to stimulate as well as to respond to an allogeneic mononuclear cells population in mixed lymphocyte reaction. Although the inability to respond in MLR can be easily obtained by gamma irradiation or mitomycin treatment of MNC, the inability to stimulate allogeneic MNC is a unique property of UV irradiation. This basic observation is the result of complex modifications induced by UV-B irradiation on antigen presentation and T cell activation as well as on the efferent loop of the immune response. We recently began a three arms study in France, involving four blood centers: in the control group, patients receive PC containing a median of 200 X 106 leukocytes; in the UV-B group, PC with a similar leukocyte content are irradiated in controlled conditions with the energy of 0.5 J/cm2; the third group is transfused with leukocyte-poor PC, containing a mean 7 X 106 leukocytes.
Immunization occurred in 5 out of 8 patients in the control group, 1 out of 9 in the leukocyte-poor group and in 1 out of 11 in the UV-B group (p=05).
These trials, along with the ongoing TRAP study in the United States will enable to know more precisely which place UV-B irradiation can have in the prevention of transfusion induced HLA alloimmunization. Extracorporeal photochemotherapy (ECP) consists in the collection of mononuclear cells, followed by their irradiation with UVA light in the presence of a photo-activable molecule-8 methoxy-psoralen being the most widely used-,
and their reinjection to a patient. Experimental and clinical data suggest that ECP has potential applications in auto-immune diseases.
We conducted an ECP pilot study in 6 patients with rheumatoid arthritis (RA) previously resistant to at least 3 slow acting drugs. Each procedure consisted of Leukocyte collection using the spectra cell separator (Cobe, USA).
Irradiation was performed with the same device developed for UV-B treatment of blood components, adapted to UVA irradiation (Vilber Lourmat, Trorcy, France).
The treatment schedule consisted in 8 ECP performed in three weeks. A significant clinical improvement occurred in all the patients at the end of the first
week. The number of tender and swollen joints, the morning stiffness as well as the Richie index were reduced in the 6 patients. Beneficial effect was prolonged up to 6 months except in one case relapsing 50 days after beginning of therapy.
Considering its excellent tolerance and efficacy, further controlled studies are warranted for this new treatment of RA.
